THE INVENTION Clause Samples
THE INVENTION. The present invention is directed to the use of the heptapeptide of angiotensin (Ang-1- 7) as biomarker for the prognosis and early decision-making of therapeutic treatment in COVID-19 patients. According to blood level of Ang-1-7, stratification of patients’ subpopulation at higher or lower risk of COVID-19 pulmonary fibrosis/sequelae is achieved. The combination of Ang-1-7 with additional markers provides means to rapidly provide the most appropriate treatment to the patients according to their risk profile ranging from mild treatment, Ang-1-7 agonists, antifibrotics or monoclonal therapeutic antibodies and/or oxygen supplementation at an early stage of the disease progression. This comprehensive patient stratification method is also of interest in the design of clinical trials so as to assess treatment efficacy according to subgroups of patients. • Early diagnosis of disease severity • Global comprehensive prediction test discriminating at-risk patients subpopulation • Therapeutic treatment decision tree based on composite index • Potential to limit post-acute sequelae for patients The technology is conducive to development of immunoassays including ELISA and CLEIA kits directly useful in clinical settings and could therefore efficiently contribute to limit clinical complications for COVID-19 patients receiving the most suitable treatment rapidly upon admission at the hospital. • COVID-19 patient stratification upon hospital admission for therapeutic treatment decision-making • Companion diagnostic for innovative treatment (therapeutic antibodies) under development • Possible implementation on automated CLEIA platforms
THE INVENTION. The Parties agree that under this Agreement, the Assignor shall assign, convey, and transfer all their interest in the following to the Assignee: [DESCRIBE WHAT IS BEING ASSIGNED] Hereinafter known as the “Assignment.”
THE INVENTION. The Parties agree that under this Agreement, the Assignor shall assign, convey, and transfer all their interest in the following to the Assignee:
THE INVENTION. The invention consists in an implant composed of magnets linked together by a wire. Through na- tural ducts—such as the esophagus—and using endoscopic tools, the magnets are positioned over the tissue to be cut (such as the wall between the esophagus and a diverticulum). The magnets strongly compress the tissue thus trapped, cutting it off from its blood supply. This results in tis- sue necrosis between the magnets and scarification at the edges, preventing an open wound. At the same time, the wire linking the magnets exerts a compression force on the remaining tissue, due to gravity affecting the magnets or to any other system creating a tension, resulting in a slow and atraumatic cutting of the tissue. Performing an anastomosis with a double MAGUS prototype.
THE INVENTION. The objective of the present invention is to provide a device for plasma generation and transport with a high efficiency over a long distance and allowing for a controlled and uniform treatment of large surfaces. The plasma is carried at a long distance from its generation to finally exit at the end of the system to treat efficiently a target area while sparing adjacent areas of tissue with improved control during treatment. This device is built to perform an ablation of mucosa (i.e. duodenal mucosa) in a minimally invasive way (endoscopically). • Homogeneity of treatment. • No inflammation due to cell-induced death. • Fast treatment (<1hour). • Versatile device (i.e. can treat any mucosa of the gastro-intestinal tract). • Ablation of the duodenal lining • Regeneration of mucosa • Insulin resistance disease (Type 2 Diabetes - TD2) and NonAlcoholic SteatoHepatitis (▇▇▇▇) • Barret’s Oesophagus
THE INVENTION. An ultra-compact holographic sensor allowing real-time monitoring of the size, concentration and shape of particles, typically from 4-40μm or larger, in confined industrial areas in order to ensure continuous monitoring and prevent fires and explosions. Due to the configuration, all the electronics of the sensor can be securely confined to avoid any risk of electrical discharge. The patent claims a compact holographic sensor which consists in using a network of endoscopic fiber array coupled to the camera sensor. The object hologram that is incident on the free entry window of the fiber array, away from the camera, is directly propagated and imaged onto the camera's sensitive sensor. We can thus achieve holographic recording of experimental volumes inaccessible by other techniques.
THE INVENTION. Inventor has invented, conceived, developed and reduced to practice a certain invention relating to the use of polymers as a soil additive. The polymers improve moisture retention of the soil and reduce fertilizer consumption of agricultural crops. This invention is referred to in this Agreement as the "Invention." The Invention also includes any and all improvements, enhancements and variations of the Invention heretofore or hereafter made or acquired by Inventor. The Invention has been patented by Inventor. The patents (referred to herein as the "Licensed Patents") covering the Invention are United States Patent Nos. 5,649,495 and 5,868,087.
THE INVENTION. The combined use of two drugs to activate latent HIV could cause a synergistic reactivation of HIV-1 production. Indeed, a proof-of-concept has been demonstrated by inventors for the coadministration of two different types of therapeutically promising HIV-1 inducers [DNA methylation inhibitors in combination with histone deacethylase inhibitors (HDACis) or histone methyltransferase inhibitors (HMTis) in combination with HDACi or NF-kappaB inducers] together with efficient cART as a thera- peutic perspective to decrease the pool of latent HIV-1 reservoirs.